Loading…
Loading…
TIVC (Tivic Health Systems, Inc.) is no longer actively trading.
This usually means the company was acquired and taken private, delisted from its exchange, or its ticker has been retired. Every price, valuation, dividend, and analyst figure on this page is frozen at the last available trading session and reads as historical reference — not a current-day signal.
TIVC does not currently pay a dividend.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for TIVC and 80,000+ other tickers.
See exactly how TIVC's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for TIVC and 80,000+ other tickers.
Tivic Health Systems, Inc. operates as a late-stage immunotherapeutics company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company’s pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications. In addition, it offers CDMO services. The company was incorporated in 2016 and is based in San Antonio, Texas.
Ticker Symbol to Change from TIVC to VBIO Effective April 28, 2026; Company Advancing Entolimod™ Toward BARDA Funding and Strategic National Stockpile Procurement While Velocity Bioworks CDMO Builds Independent Revenue Base SAN ANTONIO, April 23, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (Nasdaq: TIVC) today announced it is changing its corporate name to Valion Bio, Inc. and its Nasdaq ticker symbol from TIVC to VBIO, effective at market open on Tuesday, April 28, 2026. The CUSIP number for the company's common stock will remain unchanged.
Tivic Health Systems, Inc. (NASDAQ: TIVC - Get Free Report) Director Sheryle Bolton acquired 10,000 shares of the stock in a transaction that occurred on Wednesday, April 15th. The stock was purchased at an average price of $1.04 per share, with a total value of $10,400.00. Following the transaction, the director owned 10,000 shares in the
SAN ANTONIO, April 15, 2026 /PRNewswire/ -- Tivic Health Systems, Inc. (Nasdaq: TIVC), a clinical-stage immunotherapeutics company, today announced it has been selected to present at the U.S. Department of War's Tech Watch program on May 7, 2026. The Tech Watch initiative identifies emerging technologies with high-value defense and dual-use applications.
Tivic Health Systems (NASDAQ: TIVC - Get Free Report) and Omnicell (NASDAQ: OMCL - Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations. Earnings and Valuation This table compares Tivic
Tivic Health Systems (NASDAQ: TIVC) outlined its strategy to advance what it described as late-stage, "highly de-risked" biopharma assets over the next 12 to 24 months, with a primary focus on Entolimod, a Toll-like receptor 5 (TLR5) agonist. Speaking during the event, company executive Michael said the company is focused on immune therapies intended to improve